KURA Kura Oncology, Inc.

Kura Oncology, Inc. (NASDAQ:KURA) on Wednesday announced $50 million financing tied to advancing its menin-inhibition strategy. Launches Caspian Therapeutics With $50 Million Financing Kura said it is launching Caspian Therapeutics alongside a $50 million financing led by BVF Partners, with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Co. (NYSE:LLY), Kura Oncology, members of Kura’s leadership team, and other investors. The stated goal is to advance the company’s work in meni

Caspian Therapeutics aims to develop menin inhibitors, which have proven effective against leukemia, for diabetes and other cardiometabolic conditions.

Kura Oncology stock has delivered a solid 55.5% return over the past year, yet on broad valuation checks it still screens as expensive rather than a clear bargain. For investors, that combination of strong recent gains and a low value score raises questions about how much good news is already reflected in the current share price. The 55.5% 1 year gain highlights how strongly sentiment has improved toward Kura Oncology, which can leave less room for disappointment if expectations...

Kura's rising Komzifti sales, promising AML data and pipeline catalysts boost investor confidence and fuel KURA's gains.

Kura Oncology (KURA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Shares of Kura Oncology hit a 52-week closing high after CEO Troy Wilson bought $1.2 million worth of stock.

Companies in The News Are: DKS,KURA,NVTS,WMT

According to a filing with the SEC, Kura President and CEO Troy Edward Wilson bought 100,000 shares of common stock on August 24 for about $1.24 million in total.

Kura Oncology stock rallies as the CEO revealed another $1.24 million purchase of company shares. Wall Street continues to see massive further upside in KURA shares.

Healthcare stocks rose late Tuesday afternoon with the NYSE Healthcare Index and the State Street He

Wilson's purchase increases his total equity stake by 9% following a 62% one-year stock return, signaling confidence in the oncology biotech's pipeline.

Kura Oncology Inc. (NASDAQ:KURA) shares climbed 11.

KOMZIFTI revenue surged 57% as new patient starts climbed 35%.

Does Kura Oncology (KURA) have what it takes to be a top stock pick for momentum investors? Let's find out.

The mean of analysts' price targets for Kura Oncology (KURA) points to a 178.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Kura Oncology recently reported past second-quarter 2026 results, with revenue rising to US$20.87 million while net loss widened to US$68.33 million, alongside the publication in Blood of extensive preclinical data on its FDA-approved menin inhibitor ziftomenib (KOMZIFTI) for relapsed or refractory NPM1-mutated AML. The Blood manuscript highlights ziftomenib’s differentiated binding profile, activity across genetically defined leukemia models, and retained activity against certain...

According to a filing with the Securities and Exchange Commission, President and CEO Wilson bought 100,000 shares at an average price of $11.12.

Moby summary of Kura Oncology, Inc.'s Q2 2026 earnings call

Kura Oncology (NASDAQ:KURA) reported second-quarter net product revenue of $9.1 million from KOMZIFTI, its treatment for relapsed or refractory NPM1-mutated acute myeloid leukemia, as the company said the drug captured a majority share of new patient starts in the menin inhibitor market for that ind

Kura Oncology (KURA) delivered earnings and revenue surprises of +13.48% and +23.61%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +21.74% and +10.68%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

TELA Bio (TELA) delivered earnings and revenue surprises of -17.65% and -3.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) delivered earnings and revenue surprises of -120.00% and +1.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Cognition Therapeutics (CGTX) delivered earnings and revenue surprises of +33.33% and -120.00%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Kura Oncology (NASDAQ:KURA) presented updated results from its Phase 1 FIT-001 trial evaluating darlifarnib in combination with cabozantinib for locally advanced or metastatic renal cell carcinoma (RCC) that had progressed after prior treatment, including immunotherapy. The company’s investor call

Kura Oncology (KURA) is back in focus after announcing that updated Phase 1a data from its FIT-001 trial in advanced renal cell carcinoma will be featured in an oral presentation at the 2026 Kidney Cancer Research Summit. See our latest analysis for Kura Oncology. The FIT-001 update comes after a mixed period for Kura Oncology’s stock, with a 1-month share price return of 9.37% and a 90-day share price return of 11.04% contrasting with a 7-day share price decline of 5.15%. The 1-year total...